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Stručni članak 
Sažetak: Chlamydia trachomatis (C. trachomatis) najčešći je bakterijski uzročnik spolno-prenosivih infekcija i 
obligatna unutarstanična bakterija s jedinstvenim životnim ciklusom. Za testiranje antimikrobne osjetljivosti ovog 
učestalog patogena danas se najčešće koristi stanična kultura McCoy stanica uz imunofluorescentno bojanje za 
detekciju karakterističnih klamidijskih inkluzija. Sam postupak testiranja može se podijeliti u četiri osnovna koraka – 
predizolacijska faza, izolacija C. trachomatis u staničnoj kulturi, priprema za testiranje antimikrobne osjetljivosti te, 
najzad, faza testiranja uz određivanje minimalne inhibitorne koncentracije (MIC) i minimalne klamicidne koncentracije 
(MCC). Kako ova metoda zahtjeva preciznost i posvećivanje posebne pozornosti čimbenicima koji mogu utjecati na 
sposobnost klamidija da inficiraju stanice u kulturi, ali i na učinkovitost testiranog antibiotika uslijed različitih 
mehanizama kao što je pravodobni ulazak u stanicu, pravilno izvođenje svakog od ovih koraka je ključno kako bi se 
osigurala reproducibilnost i usporedivost dobivenih rezultata. 
 
Ključne riječi: Chlamydia trachomatis, testiranje antimikrobne osjetljivosti, stanična kultura, imunofluorescentno 
bojenje, minimalna inhibitorna koncentracija, minimalna klamicidna koncentracija 
 
Professional paper 
Abstract: Chlamydia trachomatis (C. trachomatis) is the most common bacterial agent of sexually transmitted 
infections and an obligate intracellular bacterium with a unique life cycle. Cell culture systems using McCoy cells and 
immunofluorescent staining to identify characteristic chlamydial inclusions represent the most common methodology 
employed in antimicrobial susceptibility testing of this prevalent pathogen. The testing process can be broken down into 
four technical steps – preisolation stage, isolation of C. trachomatis in cell culture, preparatory steps for antimicrobial 
susceptibility testing and, finally, testing phase with a determination of minimal inhibitory concentration (MIC) and 
minimal chlamydicidal concentration (MCC). As this technique requires precision and careful attention to conditions 
which may influence both the ability of chlamydial organisms to infect cells in culture and the efficacy of a tested 
antibiotic through mechanisms such as intracellular uptake, following these steps is pivotal in order to ensure 
reproducibility and comparability of obtained results. 
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Chlamydia trachomatis (C. trachomatis) is the most 
common bacterial agent of sexually transmitted 
infections in Croatia and around the world. The World 
Health Organization (WHO) estimates that there are over 
100 million new cases of C. trachomatis infections every 
year [1]. In the developed countries, chlamydial 
infections are most often found in young heterosexual 
adults under 25 years of age, ranging from 3 to 6% 
among those who are sexually active [2,3]. Recent study 
that investigated C. trachomatis infections among 
sexually active Croatian young women and men aged 
18–25 revealed 5.3% and 7.3% prevalence, respectively 
[4]. 
This obligate intracellular bacterium has a unique life 
cycle characterized by the transformation of an 
extracellular, infectious elementary body (EB) in the 
intracellular, noninfectious, metabolically active 
reticulate body (RB) and vice versa (Figure 1) [5]. Due to 
its small size and reliance on the biosynthetic machinery, 
C. trachomatis was once considered to be a virus; 
however, presence of a cell wall, DNA, RNA and 
ribosomes, as well as its susceptibility to antimicrobial 
agents, are undoubtedly placing this organism in the 
bacterial domain of life [6]. 
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C. trachomatis is a causative factor of a plethora of 
symptoms and clinical syndromes, ranging from 
urethritis, epididymitis and prostatitis in men, to 
cervicitis, endometritis and pelvic inflammatory disease 
in women [7]. Although molecular techniques are 
currently considered the gold standard for the detection 
of C. trachomatis, cultivation in cell culture system 
remains a method of choice – not only in terms of 
medico-legal investigations and follow-up after 
completed therapy, but also as a valuable (and thus far 
only) tool for determining the antimicrobial sensitivity of 
this microorganism [8]. 
In an era of increasing resistance to antimicrobials in 
many bacterial species, resistance has been exceedingly 
rare in C. trachomatis; the primary reason is the 
intracellular nature of the pathogen which eliminates the 
opportunity for rapid evolution of cell surface 
components [9]. In addition, not a lot of patients have 
chlamydia cultures obtained, tests of cure evaluations are 
not routinely done, and even if cultured, hardly a few 
isolates are subjected to antimicrobial susceptibility 
testing due to the laborious methodology. However, 
clinical treatment failures that have been described and 
attributed to multidrug-resistant C. trachomatis strains, 
are the reason for antimicrobial susceptibility testing and 
surveillance for resistance remain essential in detecting 








2. ANTIMICROBIAL SUSCEPTIBILITY TESTING IN 
CELL CULTURE SYSTEM 
 
Antimicrobial susceptibility testing of C. 
trachomatis differs greatly from standard procedures in 
bacteriology, since it is necessary to demonstrate the 
ability (or inability) of this pathogen to multiply in cells 
in the presence of different concentrations of antibiotics 
[11]. Its growth is assessed by the detection of the 
inclusions, which are intracellular membrane-bound 
structures that represent a sign of active chlamydial 
replication [11]. 
Today, cell culture systems using 
immunofluorescence staining to identify aforementioned 
inclusions are the most common methodology employed 
in antimicrobial susceptibility testing of C. trachomatis 
[12]. Several different cell lines of human or animal 
origin can be used for that purpose, albeit McCoy cells 
derived from mouse fibroblasts offer the most reliable 
and consistent results. HeLa (human cervical 
adenocarcinoma), HEp-2 (human epidermoid laryngeal 
carcinoma) and HL (human epithelial cells) cell cultures 
can also be employed, whilst primate kidney cell line 
BGMK and Vero cells are utilized less frequently [12]. 
Laboratory conditions such as temperature, pH, 
nutritional content of the medium, the polarity of infected 
cells and the secretion of cytokines by infected cells may 
play a role in penetration and activity of certain 
antimicrobial agents [13-15]. It has been shown that in a 
medium with a high concentration of glucose, neutral pH 
value and a higher temperature during centrifugation (33-
35 °C) one can expect a higher yield of C. trachomatis 
inclusions [14]. Furthermore, the use of polarized host 
cells results in more efficient transport and internal 
concentration of antimicrobial drug azithromycin within 
cells [15]. 
Additional variables that may influence the results 
of sensitivity testing in Chlamydiae (but which have been 
incompletely studied) include the inoculum size, the 
interval between the establishment of infection and the 
administration of an antibiotic, as well as the timing of 
antimicrobial removal [16]. In addition, it is pivotal to 
implement adequate quality control of the cell line that is 
being used for the testing purposes [5]. 
It must be noted that cell culture system for 
antimicrobial susceptibility testing of C. trachomatis is 
not completely physiologic in nature, since during 
natural infection this microorganism is usually exposed 
to antimicrobials long after the establishment of 
intracellular infection and the induction of a host 
inflammatory response [12]. Conversely, with the in vitro 
systems, tested antimicrobial drugs are usually added 
simultaneously with or shortly after the infection; hence 
the inability to detect infectious chlamydiae in cell 
cultures does not exclude a viable state that could recur 
after antibiotics are removed [17]. 
The testing process can be broken down into four 
fundamental steps – preisolation stage, isolation of C. 
trachomatis in cell culture, preparatory steps for 
antimicrobial susceptibility testing and, finally, testing 
phase with the determination of concentration values. 
Each of these steps will be explained in detail in order to 
provide comprehensive review and further 
standardization of the method. 
 
2.1  Preisolation stage 
 
Before antimicrobial susceptibility testing can be 
pursued, clinical materials for isolation of C. trachomatis 
must be collected. The most commonly used specimens 
in chlamydial susceptibility testing are cervical swabs in 
women and urethral swabs (and sometimes expressed 
prostatic secretions) in men [5]. Conjunctival swabs can 
be also used as a sample, namely in communities of the 
world where trachoma is still endemic [18]. All samples 
that can be processed in the laboratory within 24 hours 
can be held and shipped at 4 °C (on wet ice); if this is not 
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achievable, they are stored at -70 °C before isolation 
procedure can ensue [19]. 
Only swabs with a Dacron tip and an aluminum or 
plastic shaft should be used to collect specimens. Swabs 
with calcium alginate or cotton tips and wooden shafts 
are unacceptable, as growth inhibition of the organism 
can occur. Specimens should be placed in sucrose 
phosphate (2SP) transport medium (sucrose, 68.46 g; 
potassium phosphate dibasic, 2.01 g; potassium 
phosphate monobasic, 1.13 g; gentamicin, 25 µg/mL; 
nistatin, 25 µg/mL; vancomycin, 100 µg/mL; and 10%–
20% fetal calf serum, made up to a final volume of 1000 
mL, pH 7.2-7.4) and not removed before transport [5,19]. 
Growth medium must be prepared as well. Eagle's 
minimum essential medium (MEM) is used as a base, 
with a formulation that usually incorporates either Hanks' 
or Earle's balanced salts in order to provide adequate 
buffering of the medium [20]. As MEM is a simple 
medium, the recommendation is to add additional 
supplements or higher levels of serum to improve cell 
growth. Most commercially available liquid media 
already contain the appropriate bicarbonate levels, 
therefore do not require additional bicarbonate. Fetal calf 
serum (inactivated at 56 °C to inhibit components of the 
complement), glucose and cycloheximide are then added 
in order to prepare a growth medium [5]. 
The preferred cell line for isolation of C. 
trachomatis are McCoy cells, a continuous cell culture of 
adherent fibroblasts derived from the unknown tissue of 
the house mouse (Mus musculus) [21]. Those fibroblasts 
possess structurally abnormal marker chromosomes 
characteristic of strain L mouse fibroblasts. The 
subcultivation of McCoy cells should be done following 
these steps: removing the growth medium, adding 0.25% 
of trypsin-versene (EDTA) solution for 1-2 minutes, 
removing the trypsin-versene solution, waiting for the 
cells to detach from the culture vessel surface into 
suspension, adding new growth medium, and then 
reinoculating the suspension into new culture vessels [5].  
 
2.2  Isolation of C. trahcomatis in cell culture 
 
As C. trachomatis represents an organism that 
belongs to biosafety level 2 (BSL 2) agents, biosafety 
practices that include personal protective equipment, 
decontamination and appropriate biohazardous material 
waste must be followed. The specimen is inoculated by 
centrifugation onto a confluent monolayer of McCoy 
cells that support the growth of this obligate intracellular 
bacterium [22]. Inoculated cells are harvested after 48–
72 hours of growth; characteristic intracytoplasmic 
inclusions that contain substantial numbers of C. 
trachomatis elementary and reticulate bodies are 
developed upon infection. 
The cell monolayers are then reacted with either 
genus specific or species-specific fluorescein-conjugated 
monoclonal antibodies to permit specific visualization of 
the chlamydial inclusions with an epifluorescent 
microscope (Figure 2) [23]. High specificity of cell 
culture detection is achieved if a C. trachomatis major 
outer membrane protein (MOMP)–specific stain is used. 
Although monoclonal antibodies directed against the 
family-specific lipopolysaccharide (LPS) of 
Chlamydiaceae cost less, they might stain bacteria that 
share LPS antigens. LPS stains might be suitable for 
routine use, but a species-specific (MOMP) stain is 
recommended in situations requiring increased 
specificity [23]. Less specific inclusion-detection 
methods using iodine, Giemsa stain or Wright stain are 
not recommended. 
Cell culture methods can differ among laboratories, 
resulting in considerable interlaboratory variation in 
performance [24]. For isolation purposes, the shell vial 
method of culturing is a better choice than the 96-well 
microtiter plate method, as it uses a larger inoculum with 
a reduced risk for cross-contamination and thus provides 
better accuracy [22]. Some laboratories can achieve 
higher sensitivities if they perform a blind pass where an 
inoculated cell monolayer is allowed to incubate for 48–
72 hours, after which it is disrupted and used to inoculate 
a fresh monolayer that is stained after 48–72 hours of 







Figure 2 Enlarged inclusion body of C. trachomatis in 




2.3  Preparatory steps for antimicrobial 
susceptibility testing 
 
Isolated chlamydial strains that are selected for 
antimicrobial susceptibility testing must by amplified by 
multiple passages so that they infect approximately 10 to 
50% of the cells [12]. This prerequisite must be met in 
order to achieve sufficient amount and inoculum size of 5 
000 – 10 000 inclusion forming units (IFU) per well of 
the microtiter plate used for susceptibility testing [8,12]. 
These plates usually have 96 wells that contain McCoy 
cell monolayers, 24-h old and grown in the medium 
without cycloheximide and antibiotics (Figure 3). Prior 
to the inoculation of chlamydial strains, the cells are 
checked under the microscope to assess the adequacy of 
growth and to rule out eventual presence of infection. 
Antimicrobial agents should be obtained in powder 
form, weighed and adjusted for purity, and reconstituted 
according to the manufacturer's instructions. Each drug 
should be prepared as a stock solution at a concentration 
of 1024 µg/ml, according to its potency calculated from 
assay purity by high-performance liquid chromatography 
(HPLC), water content and active fraction of each 
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substance, as specified by the manufacturer [25]. Such 
stock solutions can be kept at −70 °C for a maximum 





Figure 3 Microtiter plate with suspension of McCoy 
cells for antimicrobial susceptibility testing [5] 
 
2.4  Susceptibility testing phase and 
determination of concentration values 
 
After the growth medium from the previously 
prepared microtiter plates is aspirated and discarded, 
each well can be inoculated with 100 µg of the 
previously amplified chlamydial test strain. Two batches 
of plates are incubated in parallel, and subsequently 
centrifuged for one hour at 1200 × g for at 37°C. After 
centrifugation plates should immediately be transferred 
into a thermostat at 37 °C with 5% CO2 for an additional 
two hours [5]. 
Previously prepared antimicrobial stock solutions 
are then serially diluted from the initial concentration of 
1024 µg/ml to 0.008 µg/ml in MEM containing 10% 
heat-inactivated fetal bovine serum and cycloheximide 
(1.0 μg/ml). At the end of a two-hour incubation period, 
the plates can be removed from the thermostat and the 
supernatants aspirated with multichannel pipette. In each 
well 100 µl of the appropriately diluted antimicrobial 
drug is added to the appropriate wells for a minimum 
final concentration range of 0.008 μg/ml to 8 μg/ml (and 
preferably up to 128 μg/ml) [12]. Antibiotic-free controls 
should also be used. 
After the 72-hour incubation period at 37 °C in 5% 
CO2, the cultures in one microtiter plate can be fixed 
with methanol and then stained for inclusions with either 
genus specific or species-specific fluorescein-conjugated 
monoclonal antibodies [12]. The plate is then transferred 
to a moist chamber and incubated protected from light 
for 30 minutes at a room temperature (23 °C ± 3 °C). 
Upon washing the wells twice, they can then be fixated 
with glycerol and analyzed under the invert fluorescent 
microscope (Figure 4) to determine minimal inhibitory 
concentration (MIC) values – the lowest concentration of 
an antimicrobial that will inhibit the visible growth of a 
microorganism [8,26]. 
Following the incubation of the infected cells 
overlaid with appropriate two-fold drug dilution for 72 
hours, the cells on the second plate are frozen at −70 °C 
in order to make a passage of tissue culture plates 
employing a freeze-thaw method [12]. After thawing the 
methodological procedure is similar as described for the 
first plate, i.e. cultures are passed onto new cells, 
centrifuged, overlaid with antibiotic-free medium (MEM 
with cycloheximide only), incubated for 72 hours, fixed 
and stained. The analysis of this plate under the invert 
fluorescent microscope is used to determine minimal 
chlamydicidal concentration (MCC) values, which are 
akin to minimal bactericidal concentration (MBC) in 
other domains of bacteriology, defined as a lowest 
dilution where the culture has been completely sterilized 
[5]. 
The reproducibility of C. trachomatis antimicrobial 
susceptibility testing in cell culture system relies on 
standardized definitions of MIC and MCC. To achieve 
this, it is necessary to introduce the transition point MIC 
(MICTP), which can be defined as the concentration of 
drug in which 90% or more of the inclusions are altered 
in their morphology and size [12]. The MIC can then be 
defined as the concentration of drug that is one twofold 
dilution more concentrated than the MICTP (Figure 5). 
The MCC is defined as the lowest concentration of drug 
at which there were no visible inclusions after one 
passage from the cell culture with the addition of 










Antimicrobial susceptibility testing for C. 
trachomatis (but also other chlamydial species) requires 
precision and careful attention to conditions which may 
influence both the ability of chlamydial organisms to 
infect cells in culture and the efficacy of a tested 
antibiotic through mechanisms such as intracellular 
uptake [12,26]. Therefore all four aforedescribed steps 
should be followed meticulously in order to ensure 
reproducibility and comparability of results. One cell line 
should be consistently used for C. trachomatis 
susceptibility testing; based on the literature and our 
experience, we recommend using McCoy cells. 
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A paramount methodological aspect of susceptibility 
testing in cell culture system is the endpoint utilized for 
defining the MIC, since differentiating aberrant from 
normal inclusions can be tiresome, and subjective 
interpretation may lead to severalfold variation in the 
MICs [8]. Hence, the MICTP provides a consistent 
endpoint where practically all chlamydial inclusions are 
inhibited (Figure 5), and one twofold concentration 
above the MICTP provides a reasonable standardized 
endpoint to define the MIC [12]. 
Studies on antimicrobial susceptibility of C. 
trachomatis conducted in Croatia and other countries 
using first-line and second-line antibiotics demonstrate 
good sensitivity of this microorganism, although cases of 
heterotypic resistance have been repeatedly described in 
the literature [5,10,12,27]. As we still lack information 
on whether C. trachomatis is evolving in vivo in response 
to antibiotic selection pressure, we must continue to test 
them in order to detect eventual shifts in antimicrobial 
susceptibilities in vitro. Although the methodology is 
cumbersome and not completely standardized, cell 
culture systems with immunofluorescence staining for 
the identification of chlamydial inclusions represent the 
most common methodology employed in antimicrobial 
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